Results 81 to 90 of about 61,617 (230)

A Real‐World Pharmacovigilance Study of Fruquintinib Based on the FDA Adverse Event Reporting System (FAERS) Database

Cancer Medicine, Volume 14, Issue 21, November 2025.
ABSTRACT Background Fruquintinib is a highly selective small‐molecule inhibitor that targets vascular endothelial growth factor receptors and is approved for the treatment of metastatic colorectal cancer. Given its increasing clinical adoption, a comprehensive pharmacovigilance evaluation of the adverse events (AEs) is warranted.
Yajing Xu, Dongchen Wang, Yuyan Xu
wiley   +1 more source

Adenosine Receptor-Mediated Cardioprotection—Current Limitations and Future Directions

Frontiers in Pharmacology, 2018
Since the seminal reports of adenosine receptor-mediated cardioprotection in the early 1990s, there have been a multitude of such reports in various species and preparations.
Robert D. Lasley
doaj   +1 more source

Modification of astrocytic Cx43 hemichannel activity in animal models of AD: modulation by adenosine A2A receptors [PDF]

, 2023
Daniela Madeira, Joana Domingues, Cátia R. Lopes, Paula M. Canas, Rodrigo A. Cunha, Paula Agostinho   +5 more
openalex   +1 more source

Effect and Mechanisms of Yiqi Jianpi Xiaoyu Prescription on Kidney Fibrosis on the Basis of Metabolomics and Experimental Validation

Food Science &Nutrition, Volume 13, Issue 11, November 2025.
Our results demonstrate that YQJPXY alleviates fibrosis by regulating key metabolites, including adenosine, adenine, and inosine, and activates autophagy through the A2BR/cAMP/AMPK pathway. ABSTRACT The Yiqi Jianpi Xiaoyu prescription (YQJPXY) exhibits ameliorative effects on kidney fibrosis, but the underlying mechanism related to metabolism remains ...
Keda Lu, Liqing Ye, Wenze Jiang, Tianyang Cheng, Hong Xia, Peipei Zhang, Bingbing Zhang   +6 more
wiley   +1 more source

Regadenoson in the detection of coronary artery disease

Vascular Health and Risk Management, 2008
Christiane Buhr1, Mario Gössl2, Raimund Erbel1, Holger Eggebrecht11Department of Cardiology, West-German Heart Center Essen, University of Duisburg-Essen, Essen, Germany; 2Cardiovascular Diseases, Mayo Clinic College of Medicine, Rochester, MN 55905,
Christiane Buhr, Mario Gössl, Raimund Erbel, Holger Eggebrecht   +3 more
doaj  

Adenosine Receptors As Drug Targets for Treatment of Pulmonary Arterial Hypertension

Frontiers in Pharmacology, 2017
Pulmonary arterial hypertension (PAH) is a clinical condition characterized by pulmonary arterial remodeling and vasoconstriction, which promote chronic vessel obstruction and elevation of pulmonary vascular resistance.
Allan K. N. Alencar, Guilherme C. Montes, Eliezer J. Barreiro, Roberto T. Sudo, Gisele Zapata-Sudo   +4 more
doaj   +1 more source

Cancer‐Associated Fibroblasts: Origin, Classification, Tumorigenicity, and Targeting for Cancer Therapy

MedComm, Volume 6, Issue 11, November 2025.
This review explores the multifaceted roles of cancer‐associated fibroblasts (CAFs) in tumor biology. It examines their diverse origins, dynamic activation via signaling pathways, and spatial–temporal heterogeneity, proposing an updated classification of eight distinct CAF subtypes. The review highlights CAFs' contributions to tumor growth, metastasis,
Chang Fan, Wenlong Zhu, Yuan Chen, Wanwan Zhu, Jin Ding   +4 more
wiley   +1 more source

Delineating the conformational landscape of the adenosine A2A receptor during G protein coupling

Cell, 2021
S. K. Huang, A. Pandey, D. Tran, Nicolas Villanueva, A. Kitao, R. Sunahara, Adnan Sljoka, R. Prosser   +7 more
semanticscholar   +1 more source

Caffeine in cerebrovascular research: To withdraw or not to withdraw?

Experimental Physiology, EarlyView.
Brooke R. Shepley, Kevin J. Milne, Anthony Richard Bain   +2 more
wiley   +1 more source

Multidimensional Evaluation of Lisdexamfetamine: Pharmacology, Therapeutic Use, Toxicity and Forensic Implications

Basic &Clinical Pharmacology &Toxicology, Volume 137, Issue 5, November 2025.
Structure of lisdexamfetamine dimesylate, its active metabolite d‐amphetamine and the essential amino acid l‐lysine, along with the mechanism of action and primary pharmacological and adverse effects associated with lisdexamfetamine dimesylate. TAAR1, trace amine‐associated receptor; VMAT, vesicular monoamine transporter; DAT, dopamine transporter; NAT,
Mariana Silva‐Carvalho, Daniel José Barbosa, Diana Dias da Silva, Ricardo Jorge Dinis‐Oliveira   +3 more
wiley   +1 more source